Shandong Weigao Blood Purification Products Co (SHSE:603014) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603014 Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
36 GF Score
Price ¥31.85
! 3 Warning Signs
View Full Analysis

What is Shandong Weigao Blood Purification Products Co LT-Debt-to-Total-Asset?

Shandong Weigao Blood Purification Products Co SHSE:603014 -1.64% 36 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates SHSE:603014 with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shandong Weigao Blood Purification Products Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Shandong Weigao Blood Purification Products Co's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that Shandong Weigao Blood Purification Products Co is progressively becoming more dependent on debt to grow their business.

Shandong Weigao Blood Purification Products Co  (SHSE:603014) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shandong Weigao Blood Purification Products Co LT-Debt-to-Total-Asset Related Terms

Shandong Weigao Blood Purification Products Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Blood Purification Products Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co LT-Debt-to-Total-Asset Chart

Shandong Weigao Blood Purification Products Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Shandong Weigao Blood Purification Products Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603014
36GF Score
Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Weigao Blood Purification Products Co LT-Debt-to-Total-Asset Calculation

Shandong Weigao Blood Purification Products Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.03/8608.491
=0.00

Shandong Weigao Blood Purification Products Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=10.871/8595.761
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shandong Weigao Blood Purification Products Co and its competitors.
Is Shandong Weigao Blood Purification Products Co's LT-Debt-to-Total-Asset too high?
Shandong Weigao Blood Purification Products Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's LT-Debt-to-Total-Asset compare to ABT and SYK?
Shandong Weigao Blood Purification Products Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. Shandong Weigao Blood Purification Products Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shandong Weigao Blood Purification Products Co Business Description

Address No. 7, Weigao West Road, Torch High-tech Industrial Development Zone, Shandong Province, Weihai, CHN, 264200
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
36GF Score

Get the complete analysis for SHSE:603014

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.85
Price